OHDSI MEETINGS THIS WEEK
Gold Standard Phenotype Library WG meeting - Tuesday at 9am ET
THEMIS WG meeting - Tuesday at 10am ET
The Book of OHDSI working group meeting - Tuesday at 11am ET
Zoom URL: https://columbiauniversity.zoom.us/j/258043190
OHDSI Community Call - Tuesday at 12pm ET
Common Data Model & Vocabulary WG meeting - Tuesday at 1pm ET
ATLAS workgroup meeting - Wednesday at 10am ET
Population-Level Estimation WG (Eastern Hemisphere) - Thursday at 4pm in South Korea*
You can find a full list of upcoming OHDSI meetings here:
Looking for presenters for upcoming OHDSI community calls We are looking for collaborators to share their work on upcoming OHDSI calls. If you are interested in presenting on an upcoming OHDSI call please email me at email@example.com
2019 OHDSI Symposium - CALL FOR PARTICIPATION - The deadline to submit abstracts for the collaborator showcase at this year’s symposium is two weeks away! We are accepting admissions for posters, oral presentations and software demonstrations. For more details about submission guidelines and to submit your abstract, please check out our submissions page: https://www.ohdsi.org/collaborator-showcase-submissions/
The deadline for abstract submissions is 8pm ET on Monday, June 24th, 2019.
2019 OHDSI Symposium - CREATIVE SUBMISSIONS - In addition to scientific submissions for the collaborator showcase, we’re also accepting creative submissions. We want to give collaborators a chance to showcase their special talents! This could include, playing a musical instrument, singing, an interpretive dance, or an OHDSI-inspired painting. For more information about creative submissions, please check out our creative submissions page:
The deadline for creative submission is 5pm ET on Monday, August 12th, 2019
2019 OHDSI Symposium - TUTORIALS Registration is now open for tutorials at this year’s OHDSI Symposium. Tutorials are set to take September 15th and 17th. More details about tutorials being offered is available here: https://www.ohdsi.org/tutorialworkshops2019/
Register for tutorials here: https://www.ohdsi.org/tutorialregistration2019/
A deadline is negative inspiration. Still, it’s better than no inspiration at all.
Rita Mae Brown COMMUNITY PUBLICATIONS
Computational Advances in Drug Safety: Systematic and Mapping Review of Knowledge Engineering Based Approaches.
P Natsiavas, A Malousi, C Bousquet, MC Jaulent and V Koutkias,
Frontiers in pharmacology, 2019
Drug Safety (DS) is a domain with significant public health and social impact. Knowledge Engineering (KE) is the Computer Science discipline elaborating on methods and tools for developing "knowledge-intensive" systems, depending on a conceptual "knowledge" schema and some kind of "reasoning" process. The present systematic and mapping review aims to investigate KE-based approaches employed for DS and highlight the introduced added value as well as trends and possible gaps in the domain. Journal articles published between 2006 and 2017 were retrieved from PubMed/MEDLINE and Web of Science® (873 in total) and filtered based on a comprehensive set of inclusion/exclusion criteria. The 80 finally selected articles were reviewed on full-text, while the mapping process relied on a set of concrete criteria (concerning specific KE and DS core activities, special DS topics, employed data sources, reference ontologies/terminologies, and computational methods, etc.). The analysis results are publicly available as online interactive analytics graphs. The review clearly depicted increased use of KE approaches for DS. The collected data illustrate the use of KE for various DS aspects, such as Adverse Drug Event (ADE) information collection, detection, and assessment. Moreover, the quantified analysis of using KE for the respective DS core activities highlighted room for intensifying research on KE for ADE monitoring, prevention and reporting. Finally, the assessed use of the various data sources for DS special topics demonstrated extensive use of dominant data sources for DS surveillance, i.e., Spontaneous Reporting Systems, but also increasing interest in the use of emerging data sources, e.g., observational healthcare databases, biochemical/genetic databases, and social media. Various exemplar applications were identified with promising results, e.g., improvement in Adverse Drug Reaction (ADR) prediction, detection of drug interactions, and novel ADE profiles related with specific mechanisms of action, etc. Nevertheless, since the reviewed studies mostly concerned proof-of-concept implementations, more intense research is required to increase the maturity level that is necessary for KE approaches to reach routine DS practice. In conclusion, we argue that efficiently addressing DS data analytics and management challenges requires the introduction of high-throughput KE-based methods for effective knowledge discovery and management, resulting ultimately, in the establishment of a continuous learning DS system.
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
S Crisafulli, J Sultana, Y Ingrasciotta, A Addis, P Cananzi, L Cavagna, V Conter, G D'Angelo, C Ferrajolo, L Mantovani, M Pastorello, S Scondotto and G Trifirò,
Expert opinion on drug safety, Jun 2019
Introduction: Orphan drugs are medicines intended to treat, prevent, or diagnose a rare and serious condition. The collection of pre-marketing safety and efficacy data for orphan drugs is very challenging for several reasons related to the rarity of the diseases. This highlights the need for robust post-marketing evidence generation. Real-world data sources, such as claims databases, electronic healthcare records, and disease and drug registers, have an important role in studying orphan drugs. The availability and usefulness of such resources vary from country to country. Areas covered: A detailed description of the available real-world data sources and their contribution to generating post-marketing evidence on orphan drug benefit-risk profile in Italy is provided. Expert opinion: Despite their considerable potential for rare disease research, the available Italian data sources are currently under-used and require further harmonization of data collection. The establishment of large structured and integrated nationwide data sources, tailored to respond to both research as well as regulatory requirements, is necessary to provide clinically useful information on orphan drugs as well. Such data sources should also be more accessible at the loco-regional, national and international level.
Gradients do grow on trees: a linear-time o(n)-dimensional gradient for statistical phylogenetics
A Data Element-Function Conceptual Model for Data Quality Checks
In aggregate, existing data quality (DQ) checks are currently represented in heterogeneous formats, making it difficult to compare, categorize, and index checks. This study contributes a data element-function conceptual model to facilitate the...
Comment on “How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias”
MJ Schuemie, D Madigan, PB Ryan, C Reich, MA Suchard, JA Berlin and G Hripcsak,
Pharmacoepidemiology and drug safety, May 2019 08
Identifying the DEAD: Development and Validation of a Patient-Level Model to Predict Death Status in Population-Level Claims Data